Cynata Therapeutics to provide status of stem cell product manufacturing technology

Posted: Published on February 17th, 2015

This post was added by Dr. Richardson

(MENAFN - ProactiveInvestors)

() has been granted an ASX trading halt regarding the status of its Cymerus mesenchymal stem cell product manufacture.

The halt will last until the earlier of the announcement being made or the start of trade on Thursday 19th February 2015.

Its Cymerus technology enables large scale production of mesenchymal stem cells from a single one-time donor a pivotal requirement for pharmaceutical companies moving into stem cell medicine.

Earlier this month it partner with the University of Western Australia to test its stem cells in lung fibrosis disease model.

Proactive Investors Australia is the market leader in producing news articles and research reports on ASX Small and Mid-cap stocks with distribution in Australia UK North America and Hong Kong / China.

See the article here:
Cynata Therapeutics to provide status of stem cell product manufacturing technology

Related Posts
This entry was posted in Mesenchymal Stem Cells. Bookmark the permalink.

Comments are closed.